Targeting AMPK: Basic Research and Drug Discovery —the 2nd Beijing International Conference was successfully held

2016-11-10

Sponsored by Beijing Association for Science and Technology and hosted by National Key Laboratory of Active Pharmaceutical Substances and Functions, Institute of Materia Medica of the CAMS, Targeting AMPK: Basic Research and Drug Discovery - the 2nd Beijing International Conference was successfully held on November 8 and 9, 2016 at the Institute of Materia Medica of the CAMS. The conference invited Chinese and foreign experts who had made outstanding contributions to basic research of AMPK and discovery of drugs to deliver speeches at the conference and to discuss major scientific problems and bottlenecks in basic and applied research. Dr. Haibo Zhu, professor at the Institute of Materia Medica of the CAMS, presided over the conference. Nearly 200 experts, young scholars, and postgraduates from universities, research institutes, enterprises, and hospitals attended the conference.




Prof. Lin Li, chairman of Beijing Association for Science and Technology, Prof. Jiandong Jiang, director of the Institute of Materia Medica of the CAMS, and Prof. Shuping Zhou, executive president of Tasly Institute, delivered opening speeches. All of them expressed that, with a clear theme, this conference was of great significance to promoting exchanges in basic research of AMPK and new drug research and development. Prof. Minghui Zou from Georgia State University introduced studies on AMPK as a therapeutic target for vascular disease. Prof. Huazhu Wu from Baylor College of Medicine, U.S., Prof. Ji Li from the University of Mississippi, U.S., Prof. Ming Zhao from Northwestern University, U.S., Prof. Zhenhua Wang from Yantai University, and Dr. Han Xiao from Peking University introduced latest advances in the research of the relationships between AMPK and lipid metabolism abnormality, myocardial ischemia, myocardial fibrosis, and endothelial dysfunction. Young research fellows presented reports on the prospects of AMPK activators in clinical application from the perspectives of the structure and pharmacological activity of AMPK activators and their role in the prevention of metabolic diseases and atherosclerosis.


The progress of the research project on drug efficacy and pharmacokinetics of a new AMPK drug candidate, led by Prof. Haibo Zhu, was also discussed at this conference. During the meeting, the Institute of Materia Medica of the CAMS and Tasly Pharmaceutical Group reached an agreement on the follow-up cooperation on the new AMPK activator. A youth forum was held on the sideline of the conference. Young scientists exchanged views on latest progress in domestic and overseas studies concerning the structure of AMPK, myocardial metabolic remodeling, functions of high density lipoprotein, transformation of monocyte inflammatory phenotype, and conversion of white adipose cells into beige fat cells.


As China's second high-end international academic symposium in this field, this conference initiated heated academic discussions and has played a positive role in promoting cooperation and exchanges between China and other countries in basic research and R&D of new drugs.

 

(Institute of Materia Medica)